Imatinib Completed Phase 2 Trials for Myelodysplastic Syndromes / Myeloid Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00451997Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes